With obesity rates projected to continue rising globally, there is an urgent need to understand the intricate mechanisms that contribute to metabolic diseases such as diabetes.
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug | Psychedelic Invest
TEL AVIV, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the